The Impact of Metabolic Risks and Alcohol Use on Disease Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Zobair M Younossi, MD, MPH, FAASLD
, Abstract Presenter
MASLD
2:15 PM
- 2:30 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Risk of Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease: Impact of Cardiometabolic Risk Factor Count and Its Longitudinal Changes
Ludovic Saba, MD, MSc
, Abstract Presenter
MASLD
2:30 PM
- 2:45 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Comparative Analysis of Semaglutide and Tirzepatide Use in Persons with MASLD: Implications for Progression to Cirrhosis and Complications
Ludovic Saba, MD, MSc
, Abstract Presenter
MASLD
2:45 PM
- 3:00 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Real-world clinical and economic outcomes by fibrosis stage in patients with metabolic dysfunction–associated steatohepatitis (MASH)
Manal F Abdelmalek, MD, MPH, FAASLD
, Abstract Presenter
MASLD
3:00 PM
- 3:15 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Recompensation in MASLD and MetALD related Decompensated Cirrhosis
Manal F Abdelmalek, MD, MPH, FAASLD
, Abstract Presenter
MASLD
3:15 PM
- 3:30 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Vibration-controlled transient elastography dynamics in the general population: longitudinal results from the European LiverScreen Consortium
Ludovic Saba, MD, MSc
, Abstract Presenter
MASLD
Objectives
Describe the natural history and progression patterns of MASH, including risk factors for fibrosis advancement and liver-related outcomes.
Analyze findings from large real-world data sets to identify trends, gaps, and implications for patient management and future research.